Abstract
An open, randomized, six-way crossover study was conducted in 12 healthy males to assess pharmacokinetics and bioinversion of ibuprofen enantiomers. The mean plasma terminal half-life (t1/2) of R(–)ibuprofen was 1.74 hr when intravenously infused as a racemic mixture and was 1.84 hr when intravenously infused alone. The mean t1/2 of S( + )ibuprofen was 1.77 hr when dosed as S( + )ibuprofen. Examination of values of both the absorption and disposition parameters of R(–)ibuprofen revealed that the kinetics of R(–)ibuprofen were not altered by concurrent administration of S( + )ibuprofen. In this study, there was little or no presystemic inversion of R(–)ibuprofen to its S( + )isomer. Also, 69% of the intravenous dose of R(–)ibuprofen was systemically inverted and 57.6% of the oral dose of R(–)ibuprofen lysinate was bioavailable as S ( + )ibuprofen. These results indicate that the bioinversion of R(–)ibuprofen administered orally is mainly systemic. Because bioinversion of R(–)ibuprofen is not complete, S( + )ibuprofen produced higher bioavailability of S( + )ibuprofen (92.0%) than either racemic ibuprofen (70.7%) or R(–)ibuprofen (57.6%). However, bioavailability of R(–)ibuprofen (83.6%) when dosed alone was not significantly different from when dosed as racemic mixture (80.7%).
Similar content being viewed by others
REFERENCES
R. F. N. Mills, S. S. Adams, E. E. Cliffe, W. Dickinson and J. S. Nicholson. The metabolism of ibuprofen. Xenobiotica 3:589–598 (1973).
W. J. Wechter, D. G. Loughhead, R. J. Reischer, G. J. VanGiessen and D. G. Kaiser. Enzymatic inversion at saturated carbon: Nature and mechanism of the inversion of R(−)-p-isobutyl hydratropic acid. Biochem. Biophys. Res. Commun. 61:833–837 (1974).
D. G. Kaiser, G. J. VanGiessen, R. J. Reischer and W. J. Wechter. Isomeric inversion of ibuprofen (R)-enantiomer in humans. J. Pharm. Sci. 65:269–273 (1976).
E. J. D. Lee, K. Williams, R. Day, G. Graham and D. Champion. Stereoselective disposition of ibuprofen enantiomers in man. Br. J. Clin. Pharmacol. 19:669–674 (1985).
R. J. Bopp, J. F. Nash, A. S. Ridolfo and E. R. Shephard. Stereoselective inversion of (R)-(−)-benoxaprofen to the (S)-(+)-enantiomer in humans. Drug Metab. Dispos. 7:356–359 (1979).
R. G. Simmonds, T. J. Woodage, S. M. Duff and J. N. Green. Stereospecific inversion of (R)-(−)-benoxaprofen in rat and man. Eur. J. Drug Metab. Pharmacokinet. 5:169–172 (1980).
A. Rubin, M. P. Knadler and P. P. K. Ho, L. D. Bechtol and R. L. Wolen. Stereoselective inversion of (R)-fenoprofen in humans. J. Pharm. Sci. 74:82–84 (1985).
S. Fournel and J. Caldwell. The metabolic chiral inversion of 2-phenylpropionic acid in rat, mouse and rabbit. Biochem. Pharmacol. 35:4153–4159 (1986).
V. Rossetti, A. Lombard, M. Buffa and M. C. Cassone. Studies on the Stereoisomeric inversion of ketoprofen in rats. IRCS Med. Sci. 14:256–257 (1986).
P. J. Meffin, B. C. Sallustio, Y. J. Purdie and M. E. Jones. Enantioselective disposition of 2-arylpropionic acid non-steroidal anti-inflammatory drugs. I. 2-Phenylpropionic acid disposition. J. Pharmacol. Exp. Ther. 238:280–287 (1986).
P. J. Hayball and P. J. Meffin. Enantioselective disposition of 2-arylpropionic acid non-steroidal anti-inflammatory drugs. III. Fenoprofen disposition. J. Pharmacol. Exp. Ther. 240:631–636 (1987).
A. Abas and P. J. Meffin. Enantioselective disposition of 2-arylpropionic acid non-steroidal anti-inflammatory drugs. IV. Ketoprofen disposition. J. Pharmacol. Exp. Ther. 240:637–641 (1987).
M. J. Bartels and F. A. Smith. Stereochemical inversion of haloxyfop in the Fischer 344 rat. Drug Metab. Dispos. 17:286–291 (1989).
S. S. Adams, P. Bresloff and C. G. Mason. Pharmacological differences between the optical isomers of ibuprofen: Evidence for metabolic inversion of the (−)-isomer. J. Pharm. Pharmacol. 28:256–257 (1976).
A. J. Hutt and J. Caldwell. The metabolic chiral inversion of 2-arylpropionic acids—a novel route with pharmacological consequences. J. Pharm. Pharmacol. 35:693–704 (1983).
J. Caldwell, A. J. Hutt and S. Fournel-Gigleux. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem. Pharmacol. 37:105–114 (1988).
A. J. Hutt and J. Caldwell. The importance of stereochemistry in the clinical pharmacokinetics of the 2-arylpropionic acid non-steroidal anti-inflammatory drugs. Clin. Pharmacokinet. 9:371–377 (1984).
Y. Nakamura, T. Yamaguchi, S. Hashimoto, S. Iwatani and Y. Nakagawa. Optical isomerization mechanism of R(−)-hydratropic acid derivatives. J. Pharmacobiol. Dynamics. 4:S1 (1981).
K. Williams, R. Day, R. Knihinicki and A. Duffield. The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem. Pharmacol. 35:3403–3405 (1986).
R. D. Knihinicki, K. M. Williams and R. O. Day. Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs. I. In vitro studies of ibuprofen and flurbiprofen. Biochem. Pharmacol. 38:4389–4395 (1989).
S. R. Cox. Effect of route of administration on the chiral inversion of R(−)-ibuprofen. Clin. Pharmacol. Ther. 43:146 (1988).
F. Jamali, R. Mehvar, A. S. Russell, S. Sattari, W. W. Yakimets and J. Koo. Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: Intestinal chiral inversion. J. Pharm. Sci. 81:221–225 (1992).
S. D. Hall, A. C. Rudy, P. M. Knight and D. C. Brater. Lack of presystemic inversion of (R)-to (S)-ibuprofen in humans. Clin. Pharmacol. Ther. 53:393–400 (1993).
W. Martin, G. Koselowske, H. Toberich, TH. Kerkmann, B. Mangold and J. Augustin. Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharm. Drug Dispos. 11:265–278 (1990).
K. S. Pang and K. C. Kwan. A commentary: methods and assumptions in the kinetic estimation of metabolite formation. Drug Metab. Dispos. 11:79–84 (1983).
R. Mehvar, F. Jamali and F. M. Pasutto. Liquid-chromatographic assay of ibuprofen enantiomers in plasma. Clin. Chem. 34:493–495 (1988).
A. Avgerinos and A. J. Hutt. Determination of the enantiomeric composition of ibuprofen in human plasma by high-performance liquid chromatography. J. Chromatogr. 415:75–83 (1987).
M. L. Rocci and W. J. Jusko. LAGRAN program for area and moments in pharmacokinetic analysis. Comp. Prog. Biomed. 16:203–216 (1983).
P. Veng-Pedersen. An algorithm and computer program for deconvolution in linear pharmacokinetics. J. Pharmacokin. Biopharm. 8:463–481 (1980).
M. D. Karol and S. Goodrich. Metabolite formation pharmacokinetics: Rate and extent of metabolite formation determined by deconvolution. Pharm. Res. 5:347–351 (1988).
M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982, p. 413.
K. S. Pang, W. F. Cherry, J. A. Terrell, E. H. Ulm. Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Drug Metab. Dispos. 12:309–313 (1984).
I. A. M. DeLannoy, K. S. Pang. Effect of diffusion barrier on drug and metabolite kinetics. Drug Metab. Dispos. 15:51–58 (1987).
B. P. Imbimbo, S. Daniotti, A. Vidi, D. Foschi, F. Saporiti and L. Ferrante. Discontinuous oral absorption of cimetropium bromide, a new antispasmodic drug. J. Pharm. Sci. 75:680–684 (1986).
S. A. Kaplan, R. E. Weinfeld, C. W. Abruzzo, C. W. Abruzzo and M. Lewis. Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man. J. Pharm. Sci. 61:773–778 (1972).
P. J. Carrigan and T. R. Bates. Biopharmaceutics of drugs administered in liquid-containing dosage forms I. GI absorption of griseofulvin from an oil-in-water emulsion in the rat. J. Pharm. Sci. 62:1477 (1973).
W. S. Beck, K. Dietzel, G. Geisslinger and K. Brune. Pharmacokinetics of ibuprofen enantiomers in dogs. Chirality 3:165–169 (1991).
T. A. Baillie, W. J. Adams, D. G. Kaiser, L. S. Olanoff, G. W. Halstead, H. Harpootlian and G. J. van Giessen. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans. J. Pharmacol. Exp. Ther. 249:517–523 (1989).
J. W. Cox, S. R. Cox, G. VanGiessen and M. J. Ruwart. Ibuprofen stereoisomer hepatic clearance and distribution in normal and fatty in situ perfused rat liver. J. Pharmacol. Exp. Ther. 232:636–643 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cheng, H., Rogers, J.D., Demetriades, J.L. et al. Pharmacokinetics and Bioinversion of Ibuprofen Enantiomers in Humans. Pharm Res 11, 824–830 (1994). https://doi.org/10.1023/A:1018969506143
Issue Date:
DOI: https://doi.org/10.1023/A:1018969506143